MannKind Corporation splits its revenue into 8 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was Royalty at $128.1 million, 37% of the total.
USD in millions. The percent under a figure is the change from the year before.
| Line |
FY 2026
Sep 30, 2026
|
FY 2025
Dec 31, 2025
|
FY 2024
Dec 31, 2024
|
FY 2023
Dec 31, 2023
|
FY 2022
Dec 31, 2022
|
FY 2021
Dec 31, 2021
|
FY 2020
Dec 31, 2020
|
FY 2019
Dec 31, 2019
|
FY 2018
Dec 31, 2018
|
FY 2017
Dec 31, 2017
|
FY 2016
Dec 31, 2016
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
413
|
349
|
286
|
199
|
100
|
75
|
65
|
63
|
28
|
12
|
175
|
| Royalty |
—
|
128
+25.2%
share 36.7%
|
102
share 35.8%
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| License And Service |
—
|
107
+5.8%
share 30.6%
|
101
+90.4%
share 35.3%
|
53
share 26.6%
|
—
|
36
+10.5%
share 48.1%
|
33
share 50.4%
|
—
|
—
|
—
|
—
|
| Afrezza |
—
|
75
+16.5%
share 21.4%
|
64
+16.6%
share 22.4%
|
55
+26.8%
share 27.6%
|
43
share 43.4%
|
—
|
—
|
—
|
—
|
—
|
—
|
| Product |
—
|
—
|
—
|
—
|
—
|
39
+21.2%
share 51.9%
|
32
share 49.6%
|
—
|
—
|
—
|
—
|
| Furoscix |
—
|
23
share 6.6%
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| V Go |
—
|
16
-10.5%
share 4.7%
|
18
-4.3%
share 6.4%
|
19
+47.8%
share 9.6%
|
13
share 13.0%
|
—
|
—
|
—
|
—
|
—
|
—
|
| Services |
—
|
4
-6.2%
share 1.2%
|
5
+396.4%
share 1.6%
|
1
-70.0%
share 0.5%
|
3
-91.4%
share 3.1%
|
36
share 47.7%
|
—
|
—
|
—
|
—
|
—
|
| Manufacturing Services |
—
|
2
-77.5%
share 0.5%
|
7
share 2.5%
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- MNKD (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Danbury, CT
- SEC filer status
- Large accelerated filer
- SEC CIK
- 899460
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.